Published: Mar 15, 2021
Business Intelligence (BI) platforms enable healthcare organizations to build applications that help them understand their processes and use technology to help ensure healthcare quality and control cost. BI platforms provide information delivery, integration, and analysis capabilities to healthcare organizations.
The global healthcare BI platform market is segmented on the basis of function into clinical analytics, financial analytics, operational analytics and others (regulatory reporting, etc.). In 2014, the financial analytics segment dominated the healthcare BI platform market accounting for US$ 532.0 Mn in revenue.
Financial analytics function of healthcare BI platforms fulfill the primary requirements of healthcare organizations by defining financial goals, developing business plans, and monitoring costs and revenue which drives its demand. However, clinical analytics is expected to be the fastest growing segment in the healthcare BI platform mar
Published: Mar 16, 2021
Phase 2 AFFINITY Trial of Atrasentan for Patients with Glomerular Diseases Also on Track to Begin Enrollment in the First Half of 2021
VANCOUVER, British Columbia and SEATTLE, March 16, 2021 (GLOBE NEWSWIRE) Chinook Therapeutics, Inc.. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the ALIGN Study, a pivotal phase 3 clinical trial evaluating the efficacy and safety of atrasentan, a potent and selective inhibitor of the endothelin A receptor.
“The initiation of the phase 3 ALIGN Study is an important milestone for Chinook as we advance our pipeline of programs for rare, severe chronic kidney diseases,” said Alan Glicklich, M.D., chief medical officer of Chinook. “Atrasentan has been studied in over 5,300 diabetic kidney disease patients in the phase 2 RADAR an
Published: Mar 16, 2021
NEW YORK, March 16, 2021 (GLOBE NEWSWIRE)
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will host a Virtual Rare Disease Forum on Tuesday, March 23
rd, 2021 from 1:00pm to 3:00pm ET. The event will highlight Applied Therapeutics’ development programs in Galactosemia, SORD Deficiency, and PMM2-CDG. The agenda for the event will include:
Update on ACTION-Galactosemia Clinical Development Program
Overview of SORD Deficiency, presented by Stephan L. Züchner, MD, PhD, Professor and Department Chair of Human Genetics at the University of Miami Miller School of Medicine
Published: Mar 15, 2021
The global needle free drug delivery device market is likely to witness significant growth during the course of forecast period from 2018 to 2026. Transparency Market Research (TMR) found that the global needle free drug delivery devices demonstrates fragmented structure, thanks to presence of regional and international players operating in this market. The manufacturers are largely focused toward research and development activities to launch new product and improve the existing one in order to uphold growth in the needle free drug delivery device industry. Also, various manufacturers are majorly investing in the needle free drug delivery devices to attain more market share. The launch of new technology likely to intensify competition among the key players. TMR also observed that some of the companies such as Zogenix Inc., Pharmajet Inc., Antares Pharma Inc., Glide Pharmaceutical Technologies Ltd., and Injex Pharma AG are majorly investing in North A